CL2023000118A1 - Vacuna porcina que combina una o más antígenos. - Google Patents

Vacuna porcina que combina una o más antígenos.

Info

Publication number
CL2023000118A1
CL2023000118A1 CL2023000118A CL2023000118A CL2023000118A1 CL 2023000118 A1 CL2023000118 A1 CL 2023000118A1 CL 2023000118 A CL2023000118 A CL 2023000118A CL 2023000118 A CL2023000118 A CL 2023000118A CL 2023000118 A1 CL2023000118 A1 CL 2023000118A1
Authority
CL
Chile
Prior art keywords
antigens
combines
lawsonia intracellularis
vaccine
swine vaccine
Prior art date
Application number
CL2023000118A
Other languages
English (en)
Inventor
Diaz Edgar
Stewart Cline Greg
Kroll Jeremy
Lopes Leivas Leite Fernando
B Roof Michael
Alan Steilen Mike
Original Assignee
Boehringer Ingelheim Animal Health Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Animal Health Usa Inc filed Critical Boehringer Ingelheim Animal Health Usa Inc
Publication of CL2023000118A1 publication Critical patent/CL2023000118A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a una vacuna que comprende un antígeno de Lawsonia intracellularis y uno o más antígenos de al menos un patógeno adicional seleccionado del grupo de circovirus porcino (PCV), Mycoplasma hyopneumoniae (M. hyo.) y virus del síndrome respiratorio y reproductivo porcino (PRRSV), en donde el antígeno de Lawsonia intracellularis es Lawsonia intracellularis viva.
CL2023000118A 2020-07-24 2023-01-12 Vacuna porcina que combina una o más antígenos. CL2023000118A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063055947P 2020-07-24 2020-07-24
EP20196349 2020-09-16

Publications (1)

Publication Number Publication Date
CL2023000118A1 true CL2023000118A1 (es) 2023-09-08

Family

ID=77274829

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000118A CL2023000118A1 (es) 2020-07-24 2023-01-12 Vacuna porcina que combina una o más antígenos.

Country Status (12)

Country Link
US (1) US20230241198A1 (es)
EP (1) EP4185321A2 (es)
JP (1) JP2023535066A (es)
KR (1) KR20230044474A (es)
CN (1) CN116157147A (es)
AU (1) AU2021311726A1 (es)
BR (1) BR112023001324A2 (es)
CA (1) CA3185751A1 (es)
CL (1) CL2023000118A1 (es)
CO (1) CO2023000299A2 (es)
MX (1) MX2023001024A (es)
WO (1) WO2022020593A2 (es)

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5620691A (en) 1991-06-06 1997-04-15 Stichting Centraal Diergeneeskundig Instituut Causative agent of the mystery swine disease, vaccine compositions and diagnostic kits
CA2116348C (en) 1991-08-26 2001-07-03 James E. Collins Sirs vaccine and diagnosis method
US6042830A (en) 1992-08-05 2000-03-28 Boehringer Ingelheim Vetmedica, Inc. Viral agent associated with mystery swine disease
AU2696792A (en) 1991-09-16 1993-04-27 David A Benfield Vaccine for mystery swine disease and method for diagnosis thereof
AU2684792A (en) 1991-10-14 1993-05-21 Akzo Nobel N.V. Porcine reproductive respiratory syndrome vaccine and diagnostic
DK0676467T3 (da) 1994-04-11 2002-01-21 Akzo Nobel Nv Europæiske vaccinestammer af det porcine reproduktive respiratoriske syndromvirus (PRRSV)
US5788962A (en) 1995-01-17 1998-08-04 The Curators Of The University Of Missouri DNA sequences coding for mycoplasma hyopneumoniae surface antigens, corresponding proteins and use in vaccines and diagnostic procedures
ES2223058T3 (es) 1995-03-14 2005-02-16 Akzo Nobel N.V. Expresion en la misma celula de polipeptidos del virus del sindrome reproductivo y respiratorio porcino.
US5885823A (en) 1995-06-05 1999-03-23 Nobl Laboratories, Inc. Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents
ATE199022T1 (de) 1996-10-09 2001-02-15 Akzo Nobel Nv Europäische vakzinstämme des fortplanzungs- atmungs-syndromsvirus des sweins (prrsv)
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
UA78180C2 (uk) 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
US6943152B1 (en) 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
EP1651260B2 (en) 2003-07-25 2018-06-27 Boehringer Ingelheim Vetmedica, Inc. Lawsonia intracellularis of european origin and vaccines, diagnostic agents and methods of use thereof
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US8834891B2 (en) * 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
EP2275132B1 (en) * 2005-12-29 2021-03-03 Boehringer Ingelheim Animal Health USA Inc. Multivalent PCV2 immunogenic compositions and methods of producing them
EP2371382B1 (en) 2005-12-29 2016-03-02 Boehringer Ingelheim Vetmedica, Inc. Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs
KR101619730B1 (ko) 2006-12-15 2016-05-12 베링거잉겔하임베트메디카인코퍼레이티드 Ｐｃｖ2 항원을 이용한 돼지의 치료
KR20100113582A (ko) 2008-01-23 2010-10-21 베링거잉겔하임베트메디카인코퍼레이티드 Ｐｃｖ2 마이코플라즈마 히오뉴모니에 면역원성 조성물 및 당해 조성물의 생산 방법
US8444989B1 (en) 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
ES2553879T3 (es) 2011-02-17 2015-12-14 Boehringer Ingelheim Vetmedica Gmbh Procedimiento para la producción a escala comercial de PRRSV
DK2675475T3 (en) 2011-02-17 2015-09-14 Boehringer Ingelheim Vetmed NEW EUROPEAN PRRSV TRIAL
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
AR097762A1 (es) * 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
TWI670085B (zh) * 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗

Also Published As

Publication number Publication date
CN116157147A (zh) 2023-05-23
BR112023001324A2 (pt) 2023-02-14
US20230241198A1 (en) 2023-08-03
KR20230044474A (ko) 2023-04-04
MX2023001024A (es) 2023-02-15
JP2023535066A (ja) 2023-08-15
AU2021311726A1 (en) 2023-02-09
EP4185321A2 (en) 2023-05-31
CA3185751A1 (en) 2022-01-27
WO2022020593A3 (en) 2022-02-24
WO2022020593A2 (en) 2022-01-27
CO2023000299A2 (es) 2023-01-26

Similar Documents

Publication Publication Date Title
GT201400212A (es) Vacuna de combinación contra pcv/mycoplasma hyopneumoniae/srrp
BR112018007525A2 (pt) composições imunogênicas de circovírus suíno tipo 3 e métodos de produzir e usar as mesmas
CO7160025A2 (es) Vacuna de combinación contra pcv/mycoplasma hyopneumoniae
CR20140436A (es) Vacuna de combinación contra mycoplasma hyopneumoniae
AR121361A1 (es) Vacuna
PE20061398A1 (es) Vacuna de toxoide de c. perfringens alfa
JP2016531854A5 (es)
MX2022003435A (es) Desarrollo de una vacuna novedosa atenuada viva contra la peste porcina africana basada en la eliminacion del gen i177l.
CL2012002431A1 (es) Composición inmunogénica que comprende al menos 0,2 µg de proteína recombinante orf2 del circovirus porcino de tipo 2 (pcv2) por dosis y un adyuvante seleccionado de ácido acrílico, ácido metacrílico y cualquier polímero de los mismos, la cual es efectiva para disminuir los síntomas clínicos asociados con una infección pcv2.
AR069216A1 (es) Composicion para provocar una respuesta inmune anti-mycoplasma hyopneumoniae y metodos
PH12019501766A1 (en) Porcine coronavirus vaccines
RU2016110430A (ru) Pcv2b дивергентная вакцинная композиция и способы её применения
CO6361948A2 (es) Uso de antigeno de mycoplasma bovis
BR0204470A (pt) Uso de flavivirus para a expressão de epitopos de proteìna e para o desenvolvimento de um novo virus vacinal vivo atenuado para imunização contra flavivirus e outros agentes infecciosos
RU2017124240A (ru) СПОСОБ ПОЛУЧЕНИЯ ГОТОВОЙ К ПРИМЕНЕНИЮ КОМБИНИРОВАННОЙ ВАКЦИНЫ ПРОТИВ PCV2/M.hyo
CL2023000118A1 (es) Vacuna porcina que combina una o más antígenos.
RU2018127403A (ru) Поливалентная вакцина против hyo и ее применение
CO6290700A2 (es) Una vacuna que comprende una emulsion y una bacterina tratada con calor que comprende una suspension de la bacteria muerta
RU2018137034A (ru) Комбинированная вакцина против вируса pcv2 и инфекции mycoplasma hyopneumoniae
BR112018015912A2 (pt) vírus da vacina da síndrome respiratória e reprodutiva porcina
CL2023001462A1 (es) Anticuerpos ampliamente neutralizantes contra la neuraminidasa de influenza
MX2019012220A (es) Vacunas que contienen patogenos de cerdo para uso no mixto asociado.
MX2022013080A (es) Una combinacion de vacunas para el tratamiento profilactico de un cerdo.
ATE535253T1 (de) Impfstoff gegen mycoplasma prrsv
BR112022004256A2 (pt) Vacina de combinação para administração intradérmica